| abstract |
A compound of formula (II): **(See formula)** or a tautomer thereof, or a pharmaceutically acceptable salt of each of them, wherein ring A is phenyl optionally substituted with 1-3 substituents independently selected from halo and C1-C6 alkoxy, or a 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S and optionally substituted oxidized forms of N and S, or a ring selected from **(See formula)** where R7 is C1-C6 alkyl, optionally substituted with 3-5 fluoro groups, or is C3-C6 cycloalkyl; ring B is selected from the group consisting of **(See formula)** wherein R8 is C1-C6 alkyl, or -CO-C1-C6 alkyl; X is O, S, SO or SO2; **(See formula)** is a single or double bond; ring C is phenyl or a 6-membered nitrogen-containing heteroaryl, each of which is optionally substituted with 1-4 substituents selected from halo, oxo, -OR1, C1-C6 alkyl, COOR1 and C1-C6 alkoxy, in where C1-C6 alkyl is optionally substituted with 1-5 substituents independently selected from halo, C1-C6 alkoxy and 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O , N, S and oxidized forms of N and S; each R1 is hydrogen; and wherein the term "heterocycle" refers to a non-aromatic, mono-, bi- or tricyclic ring containing 2-12 ring carbon atoms and 1-8 ring heteroatoms, provided that the ring contains at least 3 ring atoms; provided that when ring C is phenyl; then ring A is not **(See formula)** |